Human Factor IX (Factor 9) AssayMax ELISA KitHuman Factor IX (Factor 9) AssayMax ELISA Kit
Move your mouse over image or click to enlarge

Human Factor IX (Factor 9) AssayMax ELISA Kit

This assay employs a quantitative enzyme immunoassay technique that measures the specified antigen in samples.

Cat# Size Price Qty Buy
EF1009-1 96 Well Plate £276.25

Additional Information

Property Value or Rating
Manufacturer Assaypro, LLC.
Product Type AssayMax™ ELISA Kits
Samples Serum, Cell Culture, CSF
Species Human
Reactivity Human
Assay Format Sandwich ELISA
Product Size 96 Well Plate
Range 1.563-100 ng/ml
Plex Number 1
Storage Refer to component labels for details
Entrez Gene 2158
Omim 300746
UniProt P00740
UniGene Hs.522798
Special Notes For Research Use Only, Not To Be Used For Diagnostic Purposes
References * Dadehbeigi N et al. (2008) Sex hormones affect the production of recombinant Factor IX in CHO and HEK-293 cell lines. Biotechnol Lett. 30(11):1909-12 
* Fima UE et al. (2010) Long-Acting Coagulation Factors and Methods of Producing Same. Patent No: US 8476234 B2 
* Guild BC et al. (2012) Lipid nanoparticle compositions and methods for mrna delivery. Patent Application WO2012170930 A1
* Ostroff RM et al. (2012) Early detection of malignant pleural mesothelioma in asbestos-exposed individuals with a noninvasive proteomics-based surveillance tool. PLoS One. 7(10):e46091 
* Derosa F et al.(2014) Lipidic nanoparticles for mrna delivering. Patent application:WO2014089486 A1 
* Heartlein M (2014) Mrna therapeutic compositions and use to treat diseases and disorders. Patent application:WO2014152940 A1 
* Heartlein M et al. (2015) Lipid formulations for delivery of messenger rna. Patents: US 20150140070 A1. 
* DeRosa F et al. (2016) Therapeutic efficacy in a hemophilia B model using a biosynthetic mRNA liver depot system. Gene Therapy 23:699- 

" title="

* Dadehbeigi N et al. (2008) Sex hormones affect the production of recombinant Factor IX in CHO and HEK-293 cell lines. Biotechnol Lett. 30(11):1909-12 
* Fima UE et al. (2010) Long-Acting Coagulation Factors and Methods of Producing Same. Patent No: US 8476234 B2 
* Guild BC et al. (2012) Lipid nanoparticle compositions and methods for mrna delivery. Patent Application WO2012170930 A1
* Ostroff RM et al. (2012) Early detection of malignant pleural mesothelioma in asbestos-exposed individuals with a noninvasive proteomics-based surveillance tool. PLoS One. 7(10):e46091 
* Derosa F et al.(2014) Lipidic nanoparticles for mrna delivering. Patent application:WO2014089486 A1 
* Heartlein M (2014) Mrna therapeutic compositions and use to treat diseases and disorders. Patent application:WO2014152940 A1 
* Heartlein M et al. (2015) Lipid formulations for delivery of messenger rna. Patents: US 20150140070 A1. 
* DeRosa F et al. (2016) Therapeutic efficacy in a hemophilia B model using a biosynthetic mRNA liver depot system. Gene Therapy 23:699- 

" target="_blank">

* Dadehbeigi N et al. (2008) Sex hormones affect the production of recombinant Factor IX in CHO and HEK-293 cell lines. Biotechnol Lett. 30(11):1909-12 
* Fima UE et al. (2010) Long-Acting Coagulation Factors and Methods of Producing Same. Patent No: US 8476234 B2 
* Guild BC et al. (2012) Lipid nanoparticle compositions and methods for mrna delivery. Patent Application WO2012170930 A1
* Ostroff RM et al. (2012) Early detection of malignant pleural mesothelioma in asbestos-exposed individuals with a noninvasive proteomics-based surveillance tool. PLoS One. 7(10):e46091 
* Derosa F et al.(2014) Lipidic nanoparticles for mrna delivering. Patent application:WO2014089486 A1 
* Heartlein M (2014) Mrna therapeutic compositions and use to treat diseases and disorders. Patent application:WO2014152940 A1 
* Heartlein M et al. (2015) Lipid formulations for delivery of messenger rna. Patents: US 20150140070 A1. 
* DeRosa F et al. (2016) Therapeutic efficacy in a hemophilia B model using a biosynthetic mRNA liver depot system. Gene Therapy 23:699- 

Related Documents